Mereo BioPharma Group Cash Flow Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2016
Net Income	-	-29.47	-42.22	15.91	-204.54	-43.56	Upgrade
Depreciation & Amortization	-	1.06	0.89	0.8	2	1.97	Upgrade
Share-Based Compensation	-	4.92	4.77	4.13	1.95	2.05	Upgrade
Other Operating Activities	-	2.35	-12.26	-27.39	165.16	-17.88	Upgrade
Operating Cash Flow	-	-21.13	-48.82	-6.55	-35.43	-57.41	Upgrade
Capital Expenditures	-	0	-0.01	-0.67	-0.02	-0.03	Upgrade
Acquisitions	-	0	0	0	-0.44	12.59	Upgrade
Change in Investments	-	0	0	0	0	41.08	Upgrade
Other Investing Activities	-	-0.42	2	0.14	2.33	0.47	Upgrade
Investing Cash Flow	-	-0.42	1.99	-0.53	1.87	54.12	Upgrade
Share Issuance / Repurchase	-	11.09	0	97.93	23.54	-2.2	Upgrade
Debt Issued / Paid	-	-3.22	0	-0.87	19.89	-4.94	Upgrade
Other Financing Activities	-	0.1	0.2	-	-	-	Upgrade
Financing Cash Flow	-	7.97	0.2	97.07	43.42	-7.14	Upgrade
Exchange Rate Effect	-	2.82	-12.58	-1.46	-0.96	-0.44	Upgrade
Net Cash Flow	-	-13.58	-46.63	89.99	9.86	-10.43	Upgrade
Free Cash Flow	-	-21.13	-48.83	-7.22	-35.45	-57.44	Upgrade
Free Cash Flow Margin	-	-211.32%	-	-15.83%	-	-	Upgrade
Free Cash Flow Per Share	-	-0.16	-0.41	-0.07	-0.52	-4.04	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).